A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment

Journal of Viral Hepatitis

Volumn 6, Issue 2, 1999, Pages 145-150

  Pockros, P J ^a   Bain, V G ^b   Hunter, E B ^c   Conrad, A ^d   Balart, A ^e   Hollinger, F B ^f   Albert, D ^g  

^a SCRIPPS CLINIC   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VANDERBILT UNIVERSITY   (United States)

^d National Genetics Institute   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g AMGEN INC   (United States)

Author keywords

bDNA; HCV; RT PCR

Indexed keywords

ALFACON 1; ALPHA2B INTERFERON; CONSENSUS INTERFERON; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS CONCENTRATION; VIRUS DETECTION;

ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 0033012588     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00147.x     Document Type: Article

References (6)

1. McHutchinson JG. Sedghi-Vaziri A, Russell J, Schmid P, Conrad A. Is there an optimal time to measure quantitative HCV RNA to predict outcome following interferon treatment for chronic HCV infection (abstr). Hepatology 1996; 24: 356A.
2. Tong MJ, Conrad A. Viral genotypes and quantitative HCV RNA in chronic hepatitis C patients treated with interferon alpha 2b (abstr). Hepatology 1996; 24: 272A.
3. Lee VVM, Reddy KR, van Leeuwen DJ, Hollinger FB, CIFN Study Group. Undetectable HCV RNA concentrations at early time points predict sustained virological responses after treatment with consensus interferon (abstr). Gastroenterology 1997; 112: 131A.
4. Gretch DR, dela Rosa C, Carithers RL, Wilson RA, Williams B, Correy L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995; 123: 321-329.
5. Tong MJ, Reddy KR, Lee WM et al. Treatment of chronic hepatitis C with consensus Interferon: a multicenter, randomized, controlled trial. Hepatobgy 1997; 26: 747-754.
6. Jensen DM, Blatt LM, Tong MJ et al. Treatment of high viral titer chronic HCV patients with consensus interferon (CIFN) results in a significantly greater number of sustained HCV RNA responders as compared to treatment with Interferon α-2b. Hepatology 1996; 24: 275A.